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Abstract
Recently, it has become apparent that the pathogenesis of cancer is closely con-
nected with aberrantly regulated apoptotic cell death and the resulting deregulation 
of cell proliferation. The loss of equilibrium between cell proliferation and cell 
death in a tissue may play a crucial role in tumor formation. In fact, the initiation 
of uncontrolled apoptosis in a tissue may serve as the trigger for carcinogenesis. 
Various laboratory studies on animals and certain human data are suggestive that 
tumor formation requires at least two discrete events to take place in response to a 
carcinogen according to this apoptotic model of carcinogenesis. The first involves an 
elevation of apoptosis in a particular tissue due to a genetic predisposition, stress, 
or mutation. The second confers resistance to apoptosis in that same tissue result-
ing in the formation of an abnormal growth due to a dysregulation of cell number 
homeostasis. The apoptotic response of each individual to any given carcinogenic 
or other environmental stimulus is determined by their unique double set of genes 
inherited from both parents. The singular genetic traits and biochemistry of each 
individual are attributable solely to this unique combination of genes and their 
specific regulation. A general example of genetic regulation, gene dose, and control 
is provided by β-thalassemia point mutations in the beta-globin gene, which confer 
a blood disease mainly in Mediterranean populations. This mutation (heterozygous 
and homozygous, at one or both genetic loci) can cause a hereditary red blood 
cell anemia. Specific examples in relation to cancer predisposition include various 
genetic models such as the elevated levels of skin cancer among those with certain 
polymorphisms or inherited mutations in their DNA repair genes like those associ-
ated with the disorder, Xeroderma pigmentosum (XP); the high rate of skin cancer 
observed in albinos with little or no melanin; and the high incidence of lymphomas 
occurring in patients with the inherited disorder, ataxia-telangiectasia (AT). The 
mutations associated with each of these conditions can result in an elevated level 
of apoptosis in the target tissues, either constitutively or in response to particular 
carcinogens such as UV rays, and can be linked to the initiation of cancer in those 
specific tissues.
Keywords: apoptosis, carcinogenesis, albinism, β-thalassemia, Xeroderma 
pigmentosum, trichothiodystrophy, DNA repair polymorphisms, DNA repair defect 
ataxia-telangiectasia
1. Current models of carcinogenesis
Classically, experimental carcinogenesis is a complex, multistage process includ-
ing initiation, promotion, and malignant progression in which the failure of DNA 
repair mechanisms and the subsequent clonal expansion of damaged cells play a 
pivotal role. However, more recently, it has become apparent that the pathogenesis 
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of cancer is closely connected with aberrantly regulated apoptotic cell death and the 
resulting deregulation of cell proliferation [1, 2].
The Ames assay as a universal test for carcinogenicity was based on the classical 
model of carcinogenesis involving the failure of DNA repair mechanisms and the 
subsequent clonal expansion of mutated cells. However, mutagenicity in bacterial 
strains is not always an indicator of carcinogenicity since many carcinogens are 
not mutagenic [5]. Although this may be one feasible mechanism of carcinogenesis 
in laboratory models, it does not adequately fit many existing systems of carcino-
genesis which are increasingly connected with aberrantly regulated apoptotic cell 
death and the resulting deregulation of cell proliferation. Evidence for the role of 
apoptotic dysregulation in carcinogenesis comes from several sources involving 
epidemiological, histological, and comparative animal studies in different target 
organs. A number of human and mouse models also support a correlation between 
an initial elevation in apoptosis and subsequent tumorigenesis in various tissues as 
in the case of the human skin cancer model [6].
Logically, in the initial stages of carcinogenesis, the most important factor to 
consider may be that of “time.” Gene-specific mutations are known to occur ran-
domly over a long period of time, sometimes spanning several generations according 
to Darwinian doctrine. There simply may not be enough time even over the life-span 
of a single organism to produce a specific mutation, and it seems less likely that a 
specific mutation to initiate carcinogenesis could happen in response to a particular 
carcinogen. Even according to Lamarck’s alternate theory of “acquired character-
istics” in which altered genetic characteristics acquired over a length of time by a 
parent may be passed on to the next generation, it is a stretch at best. However, if 
following exposure to a carcinogen, which causes the generation of free radicals 
and DNA damage, the occurrence of a specific mutation becomes more likely; this 
likelihood is still greater at a later point in time. In effect, a specific mutation would 
be more likely to occur at a later stage of carcinogenesis than during an earlier one. 
According to the two-stage model of tumor formation (see Diagram 2), while an 
epigenetic change is more likely to occur in the first step of carcinogenesis, a genetic 
mutation is more likely to occur in the second step of carcinogenesis merely as a 
function of probability [7].
2. An apoptotic model of carcinogenesis
“Apoptosis” (falling leaves in Greek) specifically refers to one particular mode 
of cell death which is responsible for the elimination of potentially deleterious, 
mutated cells in multicellular organisms. Inducers of apoptosis include intracellular 
and extracellular stimuli such as DNA damage, oxidative stress, cell cycle disrup-
tion, hypoxia, detachment from surrounding tissue, and loss of trophic signaling [8].  
Apoptosis is regulated through at least two well-recognized pathways, both involv-
ing caspase activation. The first of these is called the “intrinsic pathway” and is 
mediated through mitochondrial release of cytochrome c, while the second is 
known as the “extrinsic pathway” and is mediated through cell surface death recep-
tors, such as the receptor for tumor necrosis factor (TNF) [9, 10]. More recently, a 
caspase-independent apoptotic pathway has also been gaining some prominence in 
apoptosis studies [11].
Apoptosis is involved in the homeostasis of cell number in tissues, and although, 
increased cell proliferation is necessary, it is certainly not sufficient for cell trans-
formation to take place. Normally, in multicellular organisms, a dynamic equilib-
rium exists between cell birth and cell death to maintain constant cell numbers 
throughout adult life. This homeostasis depends on an integrated balance between 
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apoptosis and mitosis such that these two activities are counterbalanced and 
equivalent. This homeostatic balance may contribute a critical defense mechanism 
of the cell to various genotoxic agents such as carcinogens [3].
The increased proliferation in some preneoplastic lesions is often accompanied by 
a parallel increase in apoptosis. A permanent loss in homeostatic equilibrium between 
cell proliferation and death may be a critical determinant in the transition to tumori-
genesis. Support for this comes from the islet B cells of a multistage mouse model of 
carcinogenesis in which the incidence of apoptosis increased in parallel with increas-
ing proliferation during tumor promotion, while malignancy was associated with a 
dramatic drop in apoptotic rate without a corresponding decrease in proliferation rate 
[4]. Also, in the natural human skin cancer model (not involving the application of 
inflammatory skin irritants or tumor promoters found in various suntan oils), there 
is always a fresh layer of new epidermis underlying the peeling or apoptosing cells 
as part of the normal human sunburn cycle in response to sunlight (see Figure 1 and 
Diagram 1) [12]. Tumor formation only seems to occur once the cancer cells display 
constitutively activated apoptosis and become resistant to apoptosis while continuing 
to proliferate. In fact, acquired resistance to apoptosis appears to be a pivotal event in 
immortalization and the transition to malignancy [3, 13].
Various laboratory studies on animals and certain human data are suggestive 
that tumor formation requires at least two discrete events to take place in response 
to a carcinogen according to the apoptotic model of carcinogenesis. The first 
involves an elevation of apoptosis in a particular tissue due to a genetic predisposi-
tion, stress, or mutation in response to a carcinogen. The second confers resistance 
to apoptosis in that same tissue resulting in the formation of an abnormal growth 
due to a dysregulation of cell number homeostasis (see Diagram 2). Moreover, 
there is some evidence to suggest that both these events can be reversible when 
treated with a selective apoptotic agent (see Diagram 3), and, hence, they may be 
either genetic or epigenetic in nature [6].
In this context, uncontrolled apoptosis has been directly linked to carcinogene-
sis. Scientific animal studies have shown that simply increasing the basal frequency 
Figure 1. 
The human sunburn cycle. (A) 48 h, redness & inflammation; (B) 96 h, new tissue formation; apoptosis 
(onset); (C) 120 h, apoptosis; (D) 168 h, apoptosis (end). The natural human sunburn cycle (without 
the use of any sun lotions or sunscreens) is approximately 1 week in length (7 days) from start to finish. 
Macroscopically, it consists of three phases including Inflammation, New Tissue Formation, and Apoptosis 
(visible peeling). The inflammatory phase consists of redness and inflammation commencing 20–30 minutes 
from the time of initial sun exposure. It spans grossly 2–3 days but can last up to 5 or 6 days depending upon UV 
intensity. New tissue formation is stimulated some time after initial exposure, and it is complete within 1 week. 
In the last apoptotic phase, the top layer of dead skin cells sloughs off to reveal a new tissue layer beneath. This 
process follows on from the inflammatory phase and is complete approximately 7 days following sun exposure. 
(The photos below are based on an initial exposure time of 20–30 min at a Canadian beach in February.)
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of apoptosis in murine skin cells can be linked to the development of squamous cell 
carcinomas in transgenic mice [14]. In fact, the proliferation rate in certain tissues 
like nerve cells is so slow or negligible that simply an elevation of apoptosis would 
Diagram 1. 
The human sunburn cycle. If this cycle continues unchecked in a specific exposed area on the body, it may result 
in skin cancer.
Diagram 2. 
Two-stage model of tumor formation (expanded version). Apoptosis is programmed cell death.
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be sufficient to disrupt the balance between cell birth and death in the brain or ner-
vous system even prior to the second step in the two-stage model of carcinogenesis 
connected with resistance to apoptosis and tumor formation.
Thus, according to this new model, the stimulation of apoptotic mechanisms 
becomes an important focus of study and key determinant of carcinogenic potential 
for any particular carcinogen being studied [15].
3. An example of gene regulation
The apoptotic response of each individual to any given carcinogenic or other 
environmental stimulus is determined by their unique double set of genes inherited 
from their parents. The singular genetic traits and biochemistry of each individual 
Diagram 3. 
Two-stage model of tumor formation and action of selective apoptotic agent.
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are attributable solely to this unique combination of genes and their specific regula-
tion. A general example of genetic regulation, gene dose, and control is provided 
by β-thalassemia mutations in the beta-globin gene, which confer a blood disease 
mainly in Mediterranean populations.
4. β-Thalassemia
Beta-thalassemias are a group of hereditary blood disorders affecting the 
synthesis of beta hemoglobin chains, and the results range from severe anemias 
requiring regular blood transfusions to asymptomatic individuals [16]. There are 
three main forms of the disease: thalassemia major, the most severe form with early 
presentation; thalassemia intermedia, a moderate form with clinical symptoms 
that present later in life; and, thalassemia minor, the least severe and asymptomatic 
form, which can cause moderate anemia. Frequency of this disease is 1 in 10,000 in 
the European Union and 1 in 100,000 throughout the rest of the world. Beta-
thalassemias are caused mainly by point mutations and more rarely by deletions in 
the beta-globin gene on chromosome 11 leading to reduced or absent synthesis of 
beta hemoglobin chains. The transmission of this genetic trait is usually autosomal 
recessive, but dominant mutations also exist.
In developing countries where diagnosis of thalassemia major can be delayed, 
clinically, children may display growth retardation, pallor, jaundice, poor muscula-
ture, leg ulcers, and skeletal changes among other symptoms. In developed coun-
tries where blood transfusions may be implemented sooner, patients can develop 
iron overload-related issues including endocrine complications, dilated myocar-
diopathy, liver fibrosis, and cirrhosis. The main clinical features of thalassemia 
intermedia patients are hypertrophy of erythroid marrow and related complica-
tions, gallstones, painful leg ulcers, and an increased predisposition to thrombosis. 
Thalassemia minor is not associated with any clinical symptoms except mild or 
moderate anemia in certain cases.
The a- and b-globin genes are expressed exclusively in erythroid cells and only 
during defined periods of development to ensure the correct balance of a- and 
b-globin chains which form the tetramer of various hemoglobins at different stages. 
Such tight control of these multigene clusters requires several levels of regulation [17]. 
This is dependent on regulatory regions of DNA lying in proximity or at great 
distances from the globin genes. The latter are characterized by several DNase I 
hypersensitive sites and form the locus control region (LCR). The former and latter 
sequences exert stimulatory, inhibitory, or more complex activities by interacting 
with transcription factors that bridge these DNA regions to the RNA polymerase 
machinery of the cell. Also, LCR can make physical contact with active downstream 
globin genes by forming a chromatin structure called the active chromatin hub 
(ACH) in a process termed chromatin looping [18].
The coding sequences of globin genes are generally found within three exons, 
separated by two introns. Each gene has 5′ promoter sequences, 5′ and 3′ untrans-
lated regions, and a downstream enhancer, in the case of the b-globin gene, which is 
approximately 600–900 base pairs 3′ of the poly(A) site [19].
GATA transcription factors bind the consensus sequence WGATAR, which 
is present in the flanking regions of most erythroid-specific genes. Conserved 
GATA sites are located in each of the hypersensitive sites of both alpha- and 
beta-globin gene clusters. GATA-1 and GATA-2 transcription factors are 
coexpressed in erythroid cells and are important for the regulation of ery-
throid  globin genes, in particular for the modulation of embryonic and fetal 
 hemoglobins [20].
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β-Thalassemia is mainly caused by non-deletional defects of the b-globin gene, 
mostly single base substitutions. More than 180 mutations have been identified and 
classified as beta + or beta 0 depending on whether they reduce or abolish b-globin 
chain production, respectively. These mutants can be categorized as (1) nonsense or 
frameshift mutations which produce premature terminations, (2) RNA processing 
mutants which disrupt splicing and interfere with RNA cleavage or polyadenyl-
ation, (3) transcriptional mutants which disrupt the function of the promoter, and 
(4) mutations in the initiation codon or Cap site [21].
For example, thalassemia intermedia (homozygous and heterozygous forms) 
can be caused by mutations in the promoter region (CACCC or TATA box) of the 
beta-globin gene and have been reported in a Spanish population [19]. Nuclear 
proteins related to SP1 and GT-1 factors bind to a CACCC box sequence in the 
human beta-globin enhancer adjacent to the erythroid-specific factor NFE-1 and 
ubiquitous CP1. These same proteins bind to the proximal, but not distal, CACCC 
box in the human beta-globin promoter. A CG mutation in the promoter CACCC 
box known to cause beta-thalassemia greatly decreases protein binding. Similarly, 
the same effect is produced when this mutation is introduced into the enhancer 
CACCC box [22].
A study in Germany with nonimmigrant German populations found 
that roughly two-thirds of thalassemia minor cases appear to be caused by 
Mediterranean mutations (61%), while approximately a third of cases may have 
originated as a result of local mutations such as the one that affects position −2 of 
the intron 1 splice acceptor site (IVSI-129 A-G) and a deletion of a single G in codon 
15/16 (FS 15/16 ΔG). The former finding suggests introduction due to migration 
from the Mediterranean region [23]. Similarly, while common mutations causing 
β-thalassemia major and minor occur in populations from northern, western, and 
eastern India, rare and even novel mutations may occur in some of these popula-
tions. In one Indian study, DNA sequencing of LCR HS2, 3, and 4 core sequences 
revealed a polymorphism, an A-G, in the palindromic sequence, TGGGGACCCCA, 
of LCR HS4 [24]. So, once again, the G allele could be a new evolutionary mutation 
in the Indian population, while the other mutations may have been introduced via 
migration, for example, as a result of intermarriages documented to have occurred 
in the frontier provinces during the Indo-Greek and Scythian periods of Indian 
history [25–27].
Thus, the multiple levels of gene regulation as illustrated in this example of 
the b-globin genes make up a highly and finely tuned system to determine subtle 
differences in gene expression between individuals resulting in varied production 
of b-globin chains. Such small differences or genetic polymorphisms are the reason 
for the genetic susceptibility of certain individuals to specific diseases. Similarly, in 
the human skin cancer model, the melanin pigment is the natural sunscreen of the 
human body, and the body protects itself from solar radiation by increasing mela-
nin production. The UV A and UV B components of sunlight can trigger the human 
sunburn cycle involving three phases including cell death or apoptosis, repeatedly, 
in susceptible individuals (see Table 1), and this can result in skin cancer. Melanin 
ranges in color from red and yellow (pheomelanin) to brown and black (eumelanin) 
with the latter being the most effective [28]. However, certain individuals have less 
melanin than others and are not able to produce enough melanin to fulfill this func-
tion resulting in sunburn. In fact, it is possible and worth noting that certain forms 
of medical conditions such as actinic prurigo and cheilitis prevalent among some 
Native American populations [29] may actually be misdiagnosed cases of human 
sunburn. Notably, the pinkish or reddish hue of Native Americans (originally called 
“Red Indians” by the paler European settlers), a heightened degree of photosensi-
tivity, and regular peeling of the epidermis upon exposure to sunlight all suggest a 
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lack of melanin in their skins. Since an elevation of apoptotic levels in mammalian 
skin cells has been linked to carcinogenesis, such patients predisposed to peeling 
require “apoptosis protection factor” (also called “tumor protection factor,” previ-
ously) in their sunscreens as opposed to “sun protection factor,” which mainly 
provides protection against redness and inflammation. Unfortunately, skin cancer 
statistics are not widely available for any Native American populations of North 
America at present (Table 2).
5. Examples of genes that can control apoptosis
Specific examples in relation to cancer predisposition include various genetic 
models such as the elevated levels of skin cancer among those with certain polymor-
phisms or inherited mutations in their DNA repair genes like those associated with 
the disorder, Xeroderma pigmentosum (XP); the high rate of skin cancer observed 
in albinos with little or no melanin; and the high incidence of lymphomas occurring 
in patients with the inherited disorder, ataxia-telangiectasia (AT). The mutations 
associated with each of these conditions can result in an elevated level of apoptosis in 
the target tissues, either constitutively or in response to particular carcinogens such 
as UV rays, and can be linked to the initiation of cancer in those specific tissues.
6. DNA repair defects and DNA repair polymorphisms
Mutations in the XPD helicase component of the transcription factor 
TFIIH, which is involved in basal transcription and DNA repair, can result in 
the diverse symptoms associated with both Xeroderma pigmentosum (XP) and 
I Inflammation 0–72 h
II New tissue formation 24–168 h
III Apoptosis 36–168 h
This table is based on an initial exposure of 20–30 min at noon at the beach.
[These data are based on a set of experiments conducted at Ambleside Beach in West Vancouver (British Columbia), 
Canada, in February 2010.]
Table 2. 
The three phases of sunburn.
0–1 h (Initial exposure) Redness and inflammation
24 h (Day 1) Redness and inflammation; pain
48 h (Day 2) Redness and inflammation peak; pain
72 h (Day 3) Minor peeling; less redness and inflammation
96 h (Day 4) Major peeling
120 h (Day 5) Minor peeling; itching
140 h (Day 6) Minor peeling; itching
168 h (Day 7) Recovery; visible new tissue
No use of sun preparations, sunscreen, or suntan lotion.
Approximately a 1-week/7-day cycle without the use of any sun preparations.
Table 1. 
The human sunburn cycle.
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trichothiodystrophy (TTD). Aside from the traditional mutations and deletions in 
the b-globin gene that induce β-thalassemia, it is interesting that specific mutations 
in XPD that cause TTD can also result in reduced expression of the b-globin gene, in 
addition to a number of other general clinical features. TTD is an autosomal recessive 
disorder characterized by brittle nails, brittle hair, short stature, mental retardation, 
ichthyotic skin, and, often, photosensitivity [30]. Photosensitive TTD patients tend 
to be deficient in nucleotide excision repair (NER) of UV-induced DNA damage 
and, in this aspect, resemble XP patients. XP is also an autosomal recessive disease 
that provides a useful cancer model and is characterized by extreme sensitivity of 
the skin to sunlight resulting in sunburn, sunlight-induced pigmentation changes in 
the skin, and a very high frequency of skin cancers in sun-exposed areas including 
basal or squamous cell carcinomas and melanomas. However, TTD patients display 
neither pigmentation changes nor skin cancers [31]. The explanation for this differ-
ence appears to lie in the fact that XPD has two functions and XP may be caused by 
mutations that only affect its role in NER, whereas TTD may be caused by mutations 
that affect its general transcriptional role as a subunit of the transcription factor 
TFIIH. In TTD patients, de novo synthesis of the components of TFIIH is thought to 
compensate for this deficiency in most cells, so there is little evidence for deficient 
transcription of many genes in TTD except for b-globin in humans [30]. Reduced 
repair of cyclobutane pyrimidine dimers (CPD), which do not seem to be cytotoxic 
on their own, is observed in TTD as well [32, 33]. By contrast, in XPA cells, entirely 
deficient in the repair of the two major UV-induced lesions, CPDs and (6–4) photo-
products, UV exposure results in cell death [34]. Moreover, 65% of the melanomas in 
patients with Xeroderma pigmentosum occur on areas that are routinely exposed to 
the sun like the face, head, or neck [35].
Epidemiological studies have also shown that homozygous genetic polymorphisms 
in DNA repair proteins resulting in sunburn, and a history of repeated painful 
sunburn are more correlated with a higher risk for squamous cell carcinoma than the 
wild-type or heterozygotes [36, 37]. In addition, variants within other DNA repair 
genes involved in double-stranded DNA repair triggered by UV damage have been 
found to be associated with the development of malignant melanoma [38]. Moreover, 
many cancers ranging from acute myeloid leukemia and follicular lymphoma to breast 
cancer have been associated with specific polymorphisms in DNA repair enzymes 
resulting in their reduced efficiency to cope with cellular DNA damage [39–41]. The 
inability to cope efficiently with DNA damage often results in cell death or apoptosis.
7. Albinism
There are a number of genetic models for skin cancer in humans. One such 
model is also provided by albinos, who are deficient in melanin production (mela-
nin is the pigment that protects against UV radiation and apoptotic sunburn). 
Albinos are typically characterized by pink skin, pink eyes, and white hair resulting 
from mutations in genes involved in melanin biosynthesis [42]. As a result, they 
display an increased skin cancer incidence [43]. This finding is confirmed in the 
albino hairless mouse model which displays a high incidence of UV-induced cutane-
ous cancers as well [44].
8. Ataxia-telangiectasia
Patients with the inherited disorder ataxia-telangiectasia [AT] provide 
another human cancer model since they are highly susceptible to certain cancers, 
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particularly lymphomas [45]. AT is an autosomal recessive disease which is char-
acterized by loss of coordination and telangiectasias, hypersensitivity to ionizing 
radiation, progressive neuronal degeneration, and immunodeficiency [46]. 
Interestingly, the genetic mutation in AT patients occurs in and affects a PI 3-kinase 
associated with DNA damage and has been found to be involved in the apoptotic 
response to X-irradiation [47, 48].
In addition, a constitutive elevation of IFNβ production has been demonstrated 
in fibroblasts derived from AT individuals [49]. An elevation of spontaneous 
apoptosis in AT lymphocytes has also been observed [50] thereby establishing a link 
between apoptotic potential and an increase in cancer risk. Cytokines like IFNα/β 
are known to stimulate the transcription of many proapoptotic proteins [51]. The 
transcriptional activator, NF-κB, which mediates interferon (IFN) production, is 
constitutively activated in AT cells [52] as well and is apoptotic in certain cell types 
like lymphocytes [53]. Thus, there is further evidence here to suggest that cancer 
predisposition may be connected with genetic polymorphisms that can cause 
uncontrolled apoptosis.
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